ABSTRACT
Since decades the incidence of skin cancer is clearly rising. This alarming trend also applies to melanoma. It represents the 4th most common cancer in women and 6th in men in 2015. Early recognition and treatment reduce both morbidity and mortality. Screening is the cornerstone of secondary prevention. However, access to reliable and rapid diagnosis is hampered by several factors, including accessibility to specialized medicine. One of the solutions to this problem is to collaborate with the first-line medical care through a teledermatology system. The TeleSPOT project, Teledermoscopy Smartphone-based Pigmented lesion diagnosis Online Taskforce, aims to provide a remote diagnostic aid by dermatologists to distinguish suspect pigmented skin lesions and accelerate their management.
Depuis des décennies, l'incidence des cancers cutanés est en nette augmentation. Cette tendance alarmante s'applique également au mélanome. Il représente le 4ème cancer le plus fréquent chez la femme en 2015. Une prise en charge précoce permet de réduire la morbidité et la mortalité. Le dépistage représente la pierre angulaire de la prévention secondaire. Néanmoins, l'accès au diagnostic fiable et rapide est entravé par plusieurs facteurs limitants, notamment l'accessibilité à une Médecine spécialisée. Une des solutions à cette problématique est de collaborer avec la Médecine de première ligne par le biais de la télédermatologie. Le projet TeleSPOT, acronyme de Teledermoscopy Smartphone-based Pigmented lesion diagnosis Online Taskforce, a pour objectif de fournir une aide diagnostique à distance par des dermatologues afin de trier les lésions cutanées pigmentées suspectes et d'en accélérer la prise en charge.
Subject(s)
Dermoscopy , General Practice , Melanoma , Skin Neoplasms , Telemedicine , Early Detection of Cancer , Female , Humans , Male , Melanoma/diagnosis , Skin Neoplasms/diagnosisABSTRACT
ß-Cell plasticity governs the adjustment of ß-cell mass and function to ensure normoglycemia. The study of how ß-cell mass is controlled and the identification of alternative sources of ß-cells are active fields of research. ß-Cell plasticity has been implicated in numerous physiological and pathological conditions. We developed a mice model in which we induced major ß-cell mass atrophy by implanting insulin pellets (IPI) for 7 or 10 days. The implants were then removed (IPR) to observe the timing and characteristics of ß-cell regeneration in parallel to changes in glycemia. Following IPR, the endocrine mass was reduced by 60% at day 7 and by 75% at day 10, and transient hyperglycemia was observed, which resolved within 1 wk. Five days after IPR, enhanced ß-cell proliferation and an increased frequency of small islets were observed in 7-day IPI mice. ß-Cell mass was fully restored after an additional 2 days. For the 10-day IPI group, ß-cell and endocrine mass were no longer significantly different from those of the control group at 2 wk post-IPR. Furthermore, real-time quantitative PCR analysis of endocrine structures isolated by laser capture microdissection indicated sequentially enhanced expression of the pancreatic transcription factors ß(2)/NeuroD and Pdx-1 post-IPR. Thus, our data suggest this mouse model of ß-cell plasticity not only relies on replication but also involves enhanced cell differentiation plasticity.
Subject(s)
Hypoglycemia/chemically induced , Hypoglycemic Agents/pharmacology , Insulin-Secreting Cells , Insulin/pharmacology , Islets of Langerhans , RNA, Messenger/analysis , Animals , Apoptosis/drug effects , Apoptosis/physiology , Cell Enlargement/drug effects , Cell Proliferation , Congenital Hyperinsulinism , Female , Glucose/metabolism , Glucose Transporter Type 2/metabolism , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/pathology , Insulin-Secreting Cells/physiology , Islets of Langerhans/cytology , Islets of Langerhans/drug effects , Islets of Langerhans/physiology , Laser Capture Microdissection , Mice , Nesidioblastosis , Polymerase Chain Reaction , Regeneration/drug effects , Regeneration/physiology , Time Factors , Transcription Factors/metabolismABSTRACT
A confocal holography microscope developed at the University of Victoria uniquely combines holography with a scanning confocal microscope to non-intrusively measure fluid temperatures in three-dimensions (Herring, 1997, Abe and Iwasaki, 1999, Jacquemin et al., 2005). The Confocal Scanning Laser Holography (CSLH) microscope was built and tested to verify the concept of 3D temperature reconstruction from scanned holograms. The CSLH microscope used a focused laser to non-intrusively probe a heated fluid specimen. The focused beam probed the specimen instead of a collimated beam in order to obtain different phase-shift data for each scan position. A collimated beam produced the same information for scanning along the optical propagation z-axis. No rotational scanning mechanisms were used in the CSLH microscope which restricted the scan angle to the cone angle of the probe beam. Limited viewing angle scanning from a single view point window produced a challenge for tomographic 3D reconstruction. The reconstruction matrices were either singular or ill-conditioned making reconstruction with significant error or impossible. Establishing boundary conditions with a particular scanning geometry resulted in a method of reconstruction with low error referred to as "wily". The wily reconstruction method can be applied to microscopy situations requiring 3D imaging where there is a single viewpoint window, a probe beam with high numerical aperture, and specified boundary conditions for the specimen. The issues and progress of the wily algorithm for the CSLH microscope are reported herein.
ABSTRACT
Microphthalmia-associated transcription factor (MITF) is essential for melanocyte differentiation. MITF mutations are associated with some cases of Waardenburg syndrome (WS) type 2. WS is a dominantly inherited disease characterized by auditory-pigmentary defects that result from the absence of melanocytes. The lack of mutation in MITF coding sequences in some WS2 patients suggests that unidentified factors controlling MITF expression might be involved. We show here that the cut-homeodomain transcription factor Onecut-2 (OC-2) is expressed in melanocytes and binds to the MITF gene promoter. Overexpression of OC-2 in transfected cells stimulates MITF promoter activity. Mutations that prevent OC-2 binding decrease MITF promoter activity by 75%. Based on these results, we searched in 56 WS2 patients for mutations in the OC2 gene or in OC-2 binding sites in the MITF promoter, but none was found. These results show that OC-2 stimulates MITF expression and that OC2 is a candidate gene, but not a common cause, of WS.
Subject(s)
DNA-Binding Proteins/metabolism , Homeodomain Proteins/metabolism , Melanocytes/metabolism , Transcription Factors/metabolism , Waardenburg Syndrome/genetics , Animals , Binding Sites/genetics , COS Cells , Cell Line , DNA Mutational Analysis , DNA-Binding Proteins/genetics , Gene Expression/drug effects , Homeodomain Proteins/genetics , Homeodomain Proteins/pharmacology , Humans , Melanocytes/cytology , Microphthalmia-Associated Transcription Factor , Mutation , Promoter Regions, Genetic/genetics , Transcription Factors/genetics , Transcription Factors/pharmacology , TransfectionABSTRACT
Hepatocyte nuclear factor 6 (HNF-6) is the prototype of a new class of cut homeodomain transcription factors. During mouse development, HNF-6 is expressed in the epithelial cells that are precursors of the exocrine and endocrine pancreatic cells. We have investigated the role of HNF-6 in pancreas differentiation by inactivating its gene in the mouse. In hnf6(-/-) embryos, the exocrine pancreas appeared to be normal but endocrine cell differentiation was impaired. The expression of neurogenin 3 (Ngn-3), a transcription factor that is essential for determination of endocrine cell precursors, was almost abolished. Consistent with this, we demonstrated that HNF-6 binds to and stimulates the ngn3 gene promoter. At birth, only a few endocrine cells were found and the islets of Langerhans were missing. Later, the number of endocrine cells increased and islets appeared. However, the architecture of the islets was perturbed, and their beta cells were deficient in glucose transporter 2 expression. Adult hnf6(-/-) mice were diabetic. Taken together, our data demonstrate that HNF-6 controls pancreatic endocrine differentiation at the precursor stage and identify HNF-6 as the first positive regulator of the proendocrine gene ngn3 in the pancreas. They also suggest that HNF-6 is a candidate gene for diabetes mellitus in humans.
Subject(s)
Gene Expression Regulation/physiology , Homeodomain Proteins/physiology , Nerve Tissue Proteins/physiology , Pancreas/cytology , Pancreas/physiology , Trans-Activators/physiology , Animals , Basic Helix-Loop-Helix Transcription Factors , Cell Differentiation , Hepatocyte Nuclear Factor 6 , Mice , Mice, KnockoutABSTRACT
The human core promoter binding protein (hCPBP) has been identified as a DNA-binding protein involved in the regulation of TATA box-less genes like those encoding the pregnancy-specific glycoproteins. Structurally, hCPBP contains three zinc fingers in the C-terminal domain, which is highly conserved in a number of proteins that constitute the Krüppel-like family of transcription factors. In the present work, we report the molecular cloning of the mouse CPBP (mCPBP) and its expression pattern during development as well as in adult tissues. The mouse cDNA encodes a protein of 283 amino acids that share 94.4% of identity with the hCPBP. The highest level of mCPBP transcript was detected in placenta, and its expression was lower in total embryos and in adult tissues. We also show by in situ hybridization that during embryonic development the mCPBP gene is mainly expressed in extra-embryonic structures throughout gestation; essentially no specific expression was detected in embryonic tissues. Our data demonstrate that CPBP transcript is enriched in the trophoblastic tissue and strongly suggest that its encoded polypeptide regulates target genes involved in placental development and pregnancy maintenance.
Subject(s)
Embryonic and Fetal Development , Gene Expression , Placenta/metabolism , Proto-Oncogene Proteins , Trans-Activators/genetics , Amino Acid Sequence , Animals , Cloning, Molecular , Conserved Sequence , Female , Humans , In Situ Hybridization , Kruppel-Like Factor 6 , Kruppel-Like Transcription Factors , Mice , Molecular Sequence Data , Placenta/chemistry , Pregnancy , RNA, Messenger/analysis , Trans-Activators/chemistry , Zinc FingersABSTRACT
INTRODUCTION: Three-dimensional reconstruction of histologic structures is still a real challenge. This is the reason why very few specimens are published, especially for the head. MATERIAL AND METHODS: The chondrocranium of an 18-mm human embryo was reconstructed from serial histologic sections. The three-dimensional reconstruction was based on a software used in geology and adapted to medical applications. This software was able to smooth the reconstructed model, i.e. to correct the distortions due to the histologic preparation. RESULTS: The chondrocranium model is presented. To facilitate spatial orientation, we added the reconstruction of Merkel cartilage, of Reichert cartilage, of the vertebrae, and of the cerebrum. The different portions of the chondrocranium are described. DISCUSSION: The three-dimensional result is described and advantageously compared to the rare wax models available. The morphological differences are detailed. CONCLUSION: This technique of three-dimensional reconstruction with its smoothing procedure is a very well adapted method for reconstruction of histologic structures. The results presented confirm the educational value of this tool, which is otherwise a powerful instrument of morphogenic study.
Subject(s)
Image Processing, Computer-Assisted/methods , Skull/embryology , Anatomy, Cross-Sectional , Brain/embryology , Cartilage/embryology , Cervical Vertebrae/embryology , Ear, Middle/embryology , Embryo, Mammalian , Gestational Age , Humans , Ligaments/embryology , Mandible/embryology , Mesoderm , Models, Anatomic , Software , Sphenoid Bone/embryologySubject(s)
Chromosomes, Human, Pair 19 , Chromosomes, Human, Pair 6 , DNA-Binding Proteins/genetics , Muscle Proteins , Nuclear Proteins , Trans-Activators , Transcription Factors/genetics , Animals , Cells, Cultured , Chromosome Mapping/methods , Humans , In Situ Hybridization, Fluorescence , Mice , Molecular Sequence Data , Sequence Homology , TEA Domain Transcription FactorsABSTRACT
Transcription factors of the ONECUT class, whose prototype is hepatocyte nuclear factor (HNF)-6, are characterized by the presence of a single cut domain and by a peculiar homeodomain (Lannoy, V. J., Bürglin, T. R., Rousseau, G. G., and Lemaigre, F. P. (1998) J. Biol. Chem. 273, 13552-13562). We report here the identification and characterization of human OC-2, the second mammalian member of this class. The OC-2 gene is located on human chromosome 18. The distribution of OC-2 mRNA in humans is tissue-restricted, the strongest expression being detected in the liver and skin. The amino acid sequence of OC-2 contains several regions of high similarity to HNF-6. The recognition properties of OC-2 for binding sites present in regulatory regions of liver-expressed genes differ from, but overlap with, those of HNF-6. Like HNF-6, OC-2 stimulates transcription of the hnf-3beta gene in transient transfection experiments, suggesting that OC-2 participates in the network of transcription factors required for liver differentiation and metabolism.
Subject(s)
Chromosomes, Human, Pair 18 , Homeodomain Proteins/physiology , Liver/physiology , Trans-Activators/physiology , Transcription Factors/physiology , Amino Acid Sequence , Animals , Base Sequence , COS Cells , DNA/metabolism , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/genetics , Hepatocyte Nuclear Factor 3-beta , Hepatocyte Nuclear Factor 6 , Homeodomain Proteins/chemistry , Homeodomain Proteins/genetics , Humans , Liver/chemistry , Molecular Sequence Data , Nuclear Proteins/biosynthesis , Nuclear Proteins/genetics , RNA, Messenger/metabolism , Rats , Skin/chemistry , Trans-Activators/chemistry , Trans-Activators/genetics , Transcription Factors/chemistry , Transcription Factors/genetics , Transcription, Genetic , Tumor Cells, CulturedABSTRACT
We describe the molecular cloning of murine (m) Transcriptional Enhancer Factor (TEF)-5 belonging to the TEF family of transcription factors. We show that mTEF-5 is specifically expressed in trophoblast giant cells and other extra-embryonic structures at early stages of development. At later stages, mTEF-5 is specifically expressed in the labyrinthine region of the placenta and in several embryonic tissues. We further show that the other mTEFs are differentially expressed in extraembryonic structures and in the mature placenta. Interestingly, human (h)TEF-5 is specifically expressed in the differentiated syncytiotrophoblast of the human term placenta and its expression is upregulated during the differentiation of cytotrophoblasts to syncytiotrophoblast in vitro, whereas that of hTEF-1 is down-regulated. Together with previous results describing hTEF-binding sites in the human placental lactogen-B gene enhancer, these novel observations support a role for hTEF-5 in the regulation of this gene. We further propose that the hTEF factors may play a more general role in placental gene regulation and development.
Subject(s)
DNA-Binding Proteins/genetics , Gene Expression Regulation, Developmental , Placenta/metabolism , Transcription Factors/genetics , Trophoblasts/metabolism , Amino Acid Sequence , Animals , Base Sequence , Cell Differentiation , Cells, Cultured , Cloning, Molecular , Humans , Mice , Molecular Sequence Data , Placenta/embryology , TEA Domain Transcription Factors , Trophoblasts/cytology , Up-RegulationABSTRACT
A study was conducted to test a multiresidue analytical procedure for detecting and quantifying several corticosteroids on which the European Union imposes maximum residue limits (MRLs). Primary extracts from different matrices (liver, milk, urine, faeces) were first purified on C18 cartridges. A new immunoaffinity clean-up step was included. The immunoaffinity gel was used to purify several corticosteroids simultaneously with enrichment of the corresponding fractions. The extracts were treated with an aqueous solution of pyridinium chlorochromate to fully oxidise all corticosteroids and to facilitate their extraction with dichloromethane. After evaporation, the final extract was reconstituted with toluene before injection into the GC-MS apparatus. The analysis was performed in the CI-negative ionisation mode using ammonia as the reactant gas. The estimated detection and quantification limits were, respectively, 0.25 and 0.5 ppb or lower. Overall, the method is reproducible to within 20%. Recovery is between 50 and 80% according to the corticosteroid.
Subject(s)
Adrenal Cortex Hormones/analysis , Chromatography, Affinity/methods , Gas Chromatography-Mass Spectrometry/methods , Adrenal Cortex Hormones/isolation & purification , Animals , Cattle , Feces/chemistry , Liver/chemistry , Mass Spectrometry , Milk/chemistry , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Urine/chemistryABSTRACT
We report the cloning of a cDNA encoding the human transcription factor hTEF-5, containing the TEA/ATTS DNA binding domain and related to the TEF family of transcription factors. hTEF-5 is expressed in skeletal and cardiac muscle, but the strongest expression is observed in the placenta and in placenta-derived JEG-3 choriocarcinoma cells. In correlation with its placental expression, we show that hTEF-5 binds to several functional enhansons of the human chorionic somatomammotropin (hCS)-B gene enhancer. We define a novel functional element in this enhancer comprising tandemly repeated sites to which hTEF-5 binds cooperatively. In the corresponding region of the hCS-A enhancer, which is known to be inactive, this element is inactivated by a naturally occurring single base mutation that disrupts hTEF-5 binding. We further show that the binding of the previously described placental protein f/chorionic somatomammotropin enhancer factor-1 to TEF-binding sites is disrupted by monoclonal antibodies directed against the TEA domain and that this factor is a proteolytic degradation product of the TEF factors. These results strongly suggest that hTEF-5 regulates the activity of the hCS-B gene enhancer.
Subject(s)
DNA-Binding Proteins/genetics , Gene Expression Regulation, Developmental , Placenta/metabolism , Placental Lactogen/genetics , Transcription Factors/genetics , Amino Acid Sequence , Base Sequence , Basic-Leucine Zipper Transcription Factors , Cloning, Molecular , DNA-Binding Proteins/metabolism , Enhancer Elements, Genetic/genetics , Female , Humans , Molecular Sequence Data , Placental Lactogen/metabolism , Pregnancy , TEA Domain Transcription Factors , Transcription Factors/metabolismABSTRACT
Human chorionic somatomammotropin (hCS) is encoded by two highly related genes, hCS-A and hCS-B, located in the hGH/hCS gene locus. Both genes are expressed in the syncytiotrophoblast layer of the placenta and hCS release from trophoblast cells is known to be increased by cAMP and phorbol esters. However, it remains unclear whether this regulation acts at the level of hCS gene expression or secretion and whether both genes are affected. We examined the effects of cAMP and phorbol 12-myristate 13-acetate (PMA) on the transcription of the hCS-A and hCS-B genes. Transient expression experiments revealed a 7 bp cAMP- and PMA-responsive element (CRElhCS-A) spanning nucleotides-1102 to -1096 upstream of the hCS-A gene. In contrast, the homologous sequence upstream of hCS-B (CRElhCS-B), differing from CRElhCS-A by a single substitution, shows little or no response to cAMP. In band-shift assays, the CRElhCS-A oligonucleotide was shown to bind two factors related to CREBP and AP-1, whereas CRElhCS-B only competes for one of these complexes. Finally, Southwestern analysis revealed that the CRElhCS-A element binds two ubiquitous proteins of 100 kDa and 47 kDa respectively, whereas CRElhCS-B interacts only with the 47 kDa protein. Taken together, these results suggest that a 47 kDa protein binding to the CRElhCS-A and CRElhCS-B elements is involved in the PMA response of the hCS-A and hCS-B genes, and a 100 kDa protein plays a crucial role in cAMP regulation of the hCS-A gene.
Subject(s)
Cyclic AMP/genetics , Gene Expression Regulation/genetics , Placental Lactogen/genetics , Promoter Regions, Genetic/genetics , Tetradecanoylphorbol Acetate/pharmacology , Cell Line , Cloning, Molecular , Cyclic AMP/metabolism , DNA, Recombinant , Female , Gene Expression Regulation/drug effects , Gene Transfer Techniques , Genetic Vectors/isolation & purification , HeLa Cells , Humans , Placental Lactogen/metabolism , Promoter Regions, Genetic/drug effects , Protein Binding , Transcription, Genetic/drug effectsABSTRACT
The development of complex tissues and organs during embryogenesis is accompanied by precise spatial and temporal gene regulation, which usually takes place at the level of transcription initiation by RNA polymerase II. Differential patterns of gene expression are controlled by the binding of combinatorial arrays of transcription factors to their cognate regulatory elements in the promoters and enhancers of target genes. Generally, these transcription factors belong to families that have arisen through gene duplication. Members of a given family can be identified by the fact that they possess a common DNA-binding domain. In this review, we present the current data arguing for the possible involvement of the TEF family of transcription factors, which contain the TEA DNA-binding domain, in cardiogenesis and in other developmental processes. (Trends Cardiovasc Med 1997;7:192-197). © 1997, Elsevier Science Inc.
ABSTRACT
The hCS-A and hCS-B genes encoding human chorionic somatomammotropin and the related hCS-L gene are very similar in their coding and flanking sequences. For each of these genes, downstream enhancers, varying in strength, have been identified with the help of cytotrophoblast-derived JEG-3 cells, which do not express the hCS genes. Here we study the activity of the hCS enhancers in human syncytiotrophoblast in primary culture, which naturally expresses the hCS genes. We show that the activity of the hCS-B gene enhancer is mediated by two elements, DF-3 and DF-4, whereas the hCS-L and hCS-A gene enhancers display weaker activity due to mutations in their respective DF-3 sites. Replacement of the hCS-B DF-3 site with the homologous hCS-A sequence causes hCS-B enhancer activity to decrease. Primary cytotrophoblasts differentiate in culture to form the syncytiotrophoblast. We show that during this process the production of hCS progressively increases and that concomitantly all three hCS enhancers are progressively activated. A targeted mutation in the 3' part of the DF-4 element abolishes the binding of a protein present only in syncytiotrophoblast extracts and inactivates the DF-4 element. Thus, a direct correlation exists between the appearance of this syncytiotrophoblast-specific protein and hCS enhancer activity. This primary culture model proves useful in studying the regulation of the hCS genes.
Subject(s)
Enhancer Elements, Genetic , Gene Expression Regulation , Placental Lactogen/biosynthesis , Placental Lactogen/genetics , Trophoblasts/physiology , Base Sequence , Cell Differentiation , Cell Line , Cells, Cultured , Chloramphenicol O-Acetyltransferase/biosynthesis , Chromosomes, Human, Pair 17 , Female , Humans , Mutagenesis , Placenta/cytology , Polymerase Chain Reaction , Pregnancy , Recombinant Fusion Proteins/biosynthesis , Sequence Homology, Nucleic Acid , Thymidine Kinase/biosynthesis , Transcription, Genetic , Transfection , Trophoblasts/cytologyABSTRACT
We describe the molecular cloning of two novel human and murine transcription factors containing the TEA/ATTS DNA binding domain and related to transcriptional enhancer factor-1 (TEF-1). These factors bind to the consensus TEA/ATTS cognate binding site exemplified by the GT-IIC and Sph enhansons of the SV40 enhancer but differ in their ability to bind cooperatively to tandemly repeated sites. The human TEFs are differentially expressed in cultured cell lines and the mouse (m)TEFs are differentially expressed in embryonic and extra-embryonic tissues in early post-implantation embryos. Strikingly, at later stages of embryogenesis, mTEF-3 is specifically expressed in skeletal muscle precursors, whereas mTEF-1 is expressed not only in developing skeletal muscle but also in the myocardium. Together with previous data, these results point to important, partially redundant, roles for these TEF proteins in myogenesis and cardiogenesis. In addition, mTEF-1 is strongly coexpressed with mTEF-4 in mitotic neuroblasts, while accentuated mTEF-4 expression is also observed in the gut and the nephrogenic region of the kidney. These observations suggest additional roles for the TEF proteins in central nervous system development and organogenesis.
Subject(s)
DNA-Binding Proteins/chemistry , DNA-Binding Proteins/metabolism , DNA/metabolism , Muscle Proteins , Nuclear Proteins , Trans-Activators , Transcription Factors/chemistry , Transcription Factors/metabolism , Amino Acid Sequence , Animals , Aspergillus nidulans , Base Sequence , Binding Sites , Cloning, Molecular , Drosophila , Embryonic and Fetal Development , Gene Expression Regulation, Developmental , Gestational Age , Humans , Mice , Molecular Sequence Data , Repetitive Sequences, Nucleic Acid , Sequence Homology, Amino Acid , Sequence Homology, Nucleic Acid , TEA Domain Transcription FactorsABSTRACT
The transcriptional activity of the human placental lactogen genes (choriosomatomammotropic hormone, hCS) is controlled by tissue-specific enhancers located 4 kb downstream from their respective origins of transcription. The hCS-B enhancer is the strongest; its activity is mediated by synergism between two protein-binding sites (DF-3 and DF-4). The DF-4 site possesses a potential binding sequence for TEF-1, a known transcription factor. In this paper, we show by electrophoretic mobility-shift assays and antibody supershift experiments that TEF-1 does not bind to site DF-4. Mutations in the TEF-1-like binding motif of site DF-4 prevent formation of the DNA-protein complex, called complex f, in the presence of placental JEG-3 cell extracts. When HeLa cell extracts are used, another complex (complex c) is also affected. In transient expression experiments, TKCAT constructs linked to this mutated DF-4 site exhibit greatly reduced transcriptional activity when introduced into JEG-3 cells. Some cell lines contain both protein c and protein f (the proteins forming complexes c and f); when transfected, these lines display reduced DF-4-driven activity, suggesting that the two proteins could compete for the same DF-4 sequence. We conclude that protein f is important for the placenta-specific activity of the hCS-B enhancer. By UV cross-linking, we show that protein f is actually three polypeptides ranging in size from about 12 to 21 kD.
Subject(s)
DNA-Binding Proteins/metabolism , Enhancer Elements, Genetic , Nuclear Proteins/metabolism , Placental Lactogen/genetics , Transcription Factors/metabolism , Base Sequence , Cell Line , HeLa Cells , Humans , Molecular Sequence Data , Molecular Weight , Oligodeoxyribonucleotides , Peptides/metabolism , Placental Lactogen/metabolism , Point Mutation , Protein Binding , TEA Domain Transcription FactorsABSTRACT
The human genes coding for growth hormone (hGH) and placental lactogen (choriosomatomammotropic hormone [hCS]) are clustered on chromosome 17 in the following order: 5' hGH-N hCS-L hCS-A hGH-V hCS-B 3'. So far, a single placenta-specific enhancer has been identified in the locus, 2 kb downstream from the hCS-B gene, and shown to comprise one in vitro binding site for a nuclear protein. We here provide evidence that the hCS-B enhancer is more complex: (i) protection against DNase I digestion in the 3' flanking region of the hCS-B gene reveals four binding sites (DF-1, DF-2, DF-3, and DF-4) for nuclear proteins from either placental or HeLa cells, and (ii) placenta-specific enhancer activity can be fully exerted in transient expression experiments by a 126-bp fragment comprising the DF-3 and DF-4 protein-binding sites. By dissecting this region, we show that enhancer activity is mediated by a synergy between DF-3 and DF-4. Competitions with various oligonucleotides in footprinting and gel retardation experiments indicate that the same protein or set of proteins, different in HeLa and placenta cell nuclei, interacts with sites DF-2, DF-3, and DF-4. We also studied the regions of the hCS-L and hCS-A genes which are highly similar to the hCS-B enhancer. Although they each present the same four protein-binding sites, they exhibit only minor enhancer activity.